CD274 and nonpapillary renal cell carcinoma: Although immunotherapy by PD-1/PD-L1 immune checkpoint blockade has achieved satisfying clinical results in a variety of solid tumors, including ccRCC, the low response rate of a single drug and the emergence of drug resistance have indicated the need for improving clinical benefits.